NABRIVA THERAPEUTICS AG ADS (NBRV) Covered Calls

You can sell covered calls on NABRIVA THERAPEUTICS AG ADS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for NBRV (prices last updated Mon 4:16 PM ET):

NABRIVA THERAPEUTICS AG ADS (NBRV) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.67 +0.03 2.50 2.69 340K - 0.2B
Covered Calls For NABRIVA THERAPEUTICS AG ADS (NBRV)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Oct 19 2.5 0.15 2.54 -1.6% -116.8%
Nov 16 2.5 0.25 2.44 2.5% 27.7%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.